The clinical phenotype of primary and post–polycythemia vera and postessential
thrombocythemia myelofibrosis (MF) is dominated by splenomegaly, symptomatology, a …

Human telomeres are tandem arrays that are predominantly composed of 5′-TTAGGG-3′
nucleotide sequences at the terminal ends of chromosomes. These sequences serve 2 …

PURPOSE Targeting the BCL-XL pathway has demonstrated the ability to overcome Janus
kinase inhibitor resistance in preclinical models. This phase II trial investigated the efficacy …

Background Janus kinase (JAK) inhibitors approved for myelofibrosis provide spleen and
symptom improvements but do not meaningfully improve anaemia. Momelotinib, a first-in …

PURPOSE Standard therapy for myelofibrosis comprises Janus kinase inhibitors (JAKis), yet
spleen response rates of 30%-40%, high discontinuation rates, and a lack of disease …

PURPOSE Patients with myelofibrosis who are relapsed or refractory (R/R) to Janus-
associated kinase inhibitors (JAKis) have poor clinical outcomes including dismal overall …

Fedratinib is an oral, selective Janus kinase 2 (JAK2) inhibitor. The phase II JAKARTA2
study assessed fedratinib in patients with intermediate‐or high‐risk myelofibrosis (MF) who …

Ruxolitinib (RUX) is extensively used in myelofibrosis (MF). Despite its early efficacy, most
patients lose response over time and, after discontinuation, have a worse overall survival …

Janus kinase inhibitors (JAKi) approved for myelofibrosis provide spleen and symptom
improvements but do not address anemia, a negative prognostic factor. Momelotinib, an …

Background Primary analyses of cohort 1a of the REFINE trial showed that addition of
navitoclax to ruxolitinib induced a 35% or greater reduction in spleen volume (SVR 35) and …